(Reuters) -Australian biopharmaceutical company CSL reported a 14% rise in annual earnings on Tuesday, driven by strong performance at its blood plasma business CSL Behring, and announced a A$750 million buyback in fiscal year 2026.
CSL’s Behring blood plasma unit, representing about 70% of its total revenue, benefited from strong sales of immunoglobulin products, which rose 7% to $6.06 billion.
The world’s second-largest producer of flu vaccines reported net profit after tax attributable for the year ended June 30 of $3.3 billion on a constant currency basis, higher than $3.01 billion reported last year.
CSL also said it plans to demerge its influenza vaccine division, CSL Seqirus, into a separately listed company by the end of the financial year 2026.
It declared a final dividend of $1.62 per share, compared to $1.45 per share declared a year ago.
(Reporting by John Biju and Rishav Chatterjee in Bengaluru; Editing by Vijay Kishore)
